Registry for Pulmonary Hypertension in China

Status Recruiting

Clinical Trial Summary

1. To characterize the demographics and clinical course of the patient population diagnosed as having WHO group I pulmonary arterial hypertension and WHO group IV pulmonary hypertension due to chronic thromboembolic pulmonary hypertension

2. To describe real-world outcome of Chinese patients with WHO group I pulmonary arterial hypertension and WHO group IV pulmonary hypertension due to chronic thromboembolic pulmonary hypertension

3. To evaluate differences in patient outcomes according to classification subgroup

4. To identify clinical predictors of long-term survival

5. To assess the relationship between targeted therapies for pulmonary arterial hypertension and patient outcomes

Clinical Trial Description

Data describing the natural history of idiopathic and familial pulmonary arterial hypertension were derived from a registry conducted at our institution prior to 2006. Since then, targeted therapies for pulmonary arterial hypertension have been introduced in China. It is probably that the prognosis of Chinese patients with WHO group I pulmonary arterial hypertension and WHO group IV pulmonary hypertension due to chronic thromboembolic pulmonary hypertension has also been improved as western countries. Therefore, the aim of the present study was to describe real-world outcome of Chinese patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension and identify factors that may predict outcome. Our study will provide an updated picture of the clinical course of a more broadly defined scope of pulmonary hypertension and the effects of current therapy on survival, enabling the collection of data on demographics, clinical course, treatments, and outcomes. ;

Study Design

Related Conditions & MeSH terms

Chronic Thromboembolic Pulmonary Hypertension
Death
Familial Primary Pulmonary Hypertension
Hypertension
Hypertension, Pulmonary
Pulmonary Arterial Hypertension

Clinical Trial Details

NCT number	NCT01417338
Study type	Observational
Source	Chinese Academy of Medical Sciences, Fuwai Hospital
Contact	Jian-Guo He, M.D.
Phone	86-10-88398060
Email	hejianguofw@gmail.com
Status	Recruiting
Phase	N/A
Start date	August 2009
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04076241` - Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension	N/A
Completed	`NCT05521113` - Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension
Recruiting	`NCT04972656` - Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension	N/A
Completed	`NCT04908397` - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension	Phase 1
Active, not recruiting	`NCT03288025` - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)	N/A
Completed	`NCT01959815` - Novel Screening Strategies for Scleroderma PAH
Recruiting	`NCT04266197` - Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study	Phase 2
Active, not recruiting	`NCT06092424` - High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)	N/A
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Terminated	`NCT02060487` - Effects of Oral Sildenafil on Mortality in Adults With PAH	Phase 4
Terminated	`NCT02253394` - The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study	Phase 4
Withdrawn	`NCT02958358` - FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan	N/A
Terminated	`NCT01953965` - Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.	Phase 2
Unknown status	`NCT01712997` - Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients	Phase 3
Withdrawn	`NCT01723371` - Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children	Phase 1/Phase 2
Not yet recruiting	`NCT01649739` - Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost	Phase 4
Completed	`NCT01548950` - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension	N/A
Completed	`NCT01165047` - Nitric Oxide, GeNO Nitrosyl Delivery System	Phase 2
Completed	`NCT00963027` - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil	Phase 1
Completed	`NCT00963001` - Effect of Food on the Pharmacokinetics of Oral Treprostinil	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.